Increased Production of Inflammatory Cytokines after Inoculation with Recombinant Zoster Vaccine in Mice

Increasing numbers of patients with zoster were reported recently, and recombinant zoster vaccine (Shingrix(®)) was licensed using the AS01(B) adjuvant system. Although it induces highly effective protection, a high incidence of local adverse events (regional pain, erythema, and swelling) has been r...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Tetsuo, Sawada, Akihito, Ito, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413309/
https://www.ncbi.nlm.nih.gov/pubmed/36016227
http://dx.doi.org/10.3390/vaccines10081339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413309/
https://www.ncbi.nlm.nih.gov/pubmed/36016227
http://dx.doi.org/10.3390/vaccines10081339

Ejemplares similares